SlideShare a Scribd company logo
Drug Resistant   Tuberculosis A Great Human Concern Dr.T.V.Rao MD
MDR TB –Great Human Concern
HISTORY of Tuberculosis ,[object Object]
A Tribute to Robert Koch  Discoverer of Mycobacterium Tuberculosis
Global Status ,[object Object],[object Object],[object Object]
USAID   Report on Tuberculosis in India ,[object Object]
Nobody is absolutely Immune to Tuberculosis
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Pharmacological discoveries
Selman Abraham Waksman   Nobel Prize for his discovery in 1952 .    
Pharmacological discoveries ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Introduction ,[object Object],[object Object]
Typical tubercle bacilli ,[object Object],[object Object],[object Object],[object Object]
Multi Drug Resistant Tuberculosis MDR-TB
Definition ,[object Object],[object Object],[object Object]
MDR-TB & XDR-TB THE 2008 REPORT % of MDR-TB among new TB cases 1994-2007
Classification of Drugs   ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Several Drugs becoming resistant
Basic concepts – Keep facts ,[object Object],[object Object],[object Object],[object Object]
What is multidrug-resistant tuberculosis (MDR TB)? ,[object Object]
When to suspect MDR TB ,[object Object],[object Object],[object Object],[object Object],[object Object]
What is extensively drug resistant tuberculosis (XDR TB)? ,[object Object]
Why XDR - TB a grave concern ,[object Object],[object Object]
Global Estimates 16,000 27,000 XDR TB 1,16,000, 4,24,000 MDR TB 1.6 million 8.8 million All forms TB Estimated Number of Deaths Estimated Number of Cases Classification
Extensively Drug-Resistant  Mycobacterium tuberculosis , India ,[object Object]
Global incidence of tuberculosis  Still rising as a result of the growing epidemic in Africa 0 100 200 300 400 500 600 1990 1995 2000 2005 2010 2015 Incidence per 100,000 per year World Cent. Euro,  East. Europe Est Market  East. Medit. Lat. America West. Pacific Sth East Asia AFR high HIV AFR low HIV
Are we Returning  to a Pre-antibiotic Era   Drug susceptible TB*§ MDR-TB 1990§ XDR-TB 2006§ Total DR ? Resistance to H&R –  Treatable with 2 nd  line drugs Resistance to 2 nd  line drugs – Treatment options seriously restricted Resistance to all available drugs –  No treatment options *or limited resistance manageable with 4 drug regimen - DOTS
WHO Surveillance and Incidence of MDR TB Dye et al. Global Burden of Multidrug-Resistant TB. JID 185(8), 2002 5.3 Ivory Cost 6.6 Dominican 5.8 Iran 3.4 India 6.0 Russia 2.8 China (DOTS) 7.7 China (non-DOTS) 9.0 Latvia 14.1 Estonia % MDR TB of all new cases Country
Genesis of MDR TB ,[object Object],[object Object],[object Object],[object Object]
Strains with genetic  drug resistance Wild M. TB strain Acquired drug  resistance Primary drug  resistance Spontaneous mutation Selection: inadequate treatment Transmission Development of anti-tuberculosis drug resistance Pablos-Mendez et al. WHO, 1997
Factors Contributing to Development  and Spread of MDR and XDR TB ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],Mechanism of resistance
[object Object],[object Object],[object Object],[object Object],Mechanism of resistance
Gene location associated  Drug-Resistant M.tuberculosis ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Drug Susceptibility Testing
Susceptibility Testing ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Drug susceptibility testing (DST) ,[object Object],[object Object],[object Object],[object Object]
Drug susceptibility Testing ,[object Object],[object Object]
Other accredited  Methods ,[object Object],[object Object]
Drug susceptibility testing (DST ) ,[object Object]
Detection of Rifampicin Drug susceptibility testing (DST) is more important . ,[object Object],[object Object]
Drug susceptibility testing ,[object Object]
Secondary Drugs testing:[lack of standardized methods!] ,[object Object],[object Object],[object Object],[object Object],[object Object]
MODS   M icroscopic   O bservation of   D rug Susceptibility  T esting
MODS affordable Technically Feasible  ,[object Object]
Review Article in Indian Journal of Medical Microbiology ,[object Object]
Observation of Grwoth in liquid Media ,[object Object]
Least time required for detection of MDR ,[object Object]
MODS more streamlined ,[object Object]
Inverted Microscope a minimal need ,[object Object]
MODS for detection of  MDR - TB ,[object Object]
Advantages of MODS methodology in MDR detection ,[object Object],[object Object],[object Object],[object Object]
Performing MODS Assay ,[object Object],[object Object]
MODS Assay ( Contd) ‏ ,[object Object],[object Object],[object Object]
Sample layout on MODS plate  (2 samples per plate) No plate contained 2 samples from the same patient
Drug susceptibility Testing In MODS ,[object Object],[object Object],[object Object],[object Object],[object Object]
Differentiation from Typical and Atypical Mycobacterium ,[object Object]
In MODS growth is identified by cording on Microscopy
MODS assay ( Contd) ‏ ,[object Object]
Observation of growth in MODS ,[object Object]
MODS in Atypical Mycobacterium ,[object Object]
Contamination in MODS Assay ,[object Object],[object Object]
Honduras study comparing the LJ medium ,[object Object]
PCR: Molecular susceptibility testing RMP resistance INH resistance Hain Genotype MTBDR Hain Genotype MTBDR INNO-LiPA Rif.TB assay
Confirming  MODS  results ,[object Object]
MODS  and  MDR  detection ,[object Object],[object Object],[object Object]
Why MODS is a better method for MDR TB detection ,[object Object],[object Object]
Biosafety concerns in MODS technology ,[object Object]
Lower Grade Biosafety  is adequate
N 95 mask protects from Biohazard
No transfer of Materials needed in MODS ,[object Object]
Computer pattern recognition of  Mycobacterium tuberculosis in MODS culture
Automation in MODS
M . tuberculosis  in MODS x10 objective  (sputum sample inoculation ) Day 6  Day 16 Day 17 Day 7  Day 8  Day 9  Day 10  Day 11  Day 12  Day 13  Day 14  Day 15
MODS can be used in Extra pulmonary Tuberculosis
Draw backs of MODS ,[object Object]
Other WHO-Endorsed Tools ,[object Object],[object Object],[object Object],[object Object],[object Object]
WHO Controls the Tuberculosis related work ,[object Object]
XDR-TB in South Africa August 2006 ,[object Object],[object Object],[object Object],[object Object],[object Object]
Molecular Fingerprinting ,[object Object],[object Object],[object Object]
CDC Updates Guidelines for Nucleic Acid Amplification Techniques to Diagnose Tuberculosis ,[object Object],[object Object],[object Object]
Selection from automated systems for molecular and bacteriological rapid diagnostics ,[object Object],[object Object],[object Object],[object Object],[object Object]
Microscopy and Culturing still a top priority
Is PCR methods a solution ? ,[object Object]
No testing method replaces clinical assessment
Extreme Drug resistant Tuberculosis (XDR-TB) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
XDR-TB: 8/23/06   ,[object Object],[object Object],[object Object],[object Object]
Czech Republic The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.  Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.    WHO 2005. All rights reserved Ecuador Georgia Argentina Bangladesh Germany Republic of Korea Armenia Russian Federation South Africa Portugal Latvia Mexico Peru USA Brazil UK Sweden Thailand Chile Based on information provided to WHO Stop TB Department  13 September 2007   Spain Islamic Republic of Iran China, Hong Kong SAR France Japan Norway Canada Italy Netherlands Estonia Lithuania Ireland Romania Israel Azerbaijan Poland Slovenia  India Australia Mozambique Vietnam Countries with confirmed XDR-TB cases as of September 2007
Summary  Drug resistant TB ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Health Care Workers and MDR TB ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Koch failed to conquer tuberculosis, which still causes enormous health problems worldwide 100 years after his Nobel award.   ,[object Object],[object Object]
Are there any solutions for effective Diagnosis in TB ?
Many more powerful hands needed to Control  Tuberculosis
Contribute your Knowledge, Wisdom, to prevent spread and control of Tuberculosis
Created by Dr.T.V.Rao MD for  ‘e’ learning  Programme Email [email_address]

More Related Content

What's hot

Multi Drug Resistant Tuberculosis
Multi Drug Resistant Tuberculosis Multi Drug Resistant Tuberculosis
Multi Drug Resistant Tuberculosis
Amer Alboush
 
The treatment of multi drug resistant tuberculosis (mdr-tb) with sirturo (be...
The  treatment of multi drug resistant tuberculosis (mdr-tb) with sirturo (be...The  treatment of multi drug resistant tuberculosis (mdr-tb) with sirturo (be...
The treatment of multi drug resistant tuberculosis (mdr-tb) with sirturo (be...Kishore Chinna
 
DRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENT
DRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENTDRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENT
DRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENT
Dr.Lalit Kumar
 
MDR-TB
MDR-TBMDR-TB
MDR-TB
Abino David
 
Mdr tuberculosis
Mdr tuberculosisMdr tuberculosis
Mdr tuberculosis
Gyanshankar Mishra
 
Mdr tb & xdr tb ppt.
Mdr tb & xdr tb ppt. Mdr tb & xdr tb ppt.
Mdr tb & xdr tb ppt.
Silajit Dutta
 
Principle of mdr tb management
Principle of mdr tb managementPrinciple of mdr tb management
Principle of mdr tb management
Dr. Kaliprasanna chatterjee
 
New agents for the treatment of drug resistant Mycobacterium Tuberculosis
New agents for the treatment of drug resistant Mycobacterium TuberculosisNew agents for the treatment of drug resistant Mycobacterium Tuberculosis
New agents for the treatment of drug resistant Mycobacterium Tuberculosis
Areej Abu Hanieh
 
Mdr xdr TB
Mdr xdr TBMdr xdr TB
Recent Advances in Multidrug-Resistant TB of HIV/TB coinfection.2013
Recent Advances in Multidrug-Resistant TB of HIV/TB coinfection.2013Recent Advances in Multidrug-Resistant TB of HIV/TB coinfection.2013
Recent Advances in Multidrug-Resistant TB of HIV/TB coinfection.2013
Hivlife Info
 

What's hot (12)

Multi Drug Resistant Tuberculosis
Multi Drug Resistant Tuberculosis Multi Drug Resistant Tuberculosis
Multi Drug Resistant Tuberculosis
 
The treatment of multi drug resistant tuberculosis (mdr-tb) with sirturo (be...
The  treatment of multi drug resistant tuberculosis (mdr-tb) with sirturo (be...The  treatment of multi drug resistant tuberculosis (mdr-tb) with sirturo (be...
The treatment of multi drug resistant tuberculosis (mdr-tb) with sirturo (be...
 
DRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENT
DRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENTDRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENT
DRUG RESISTANT TUBERCULOSIS,DIAGNOSIS AND TREATMENT
 
MDR-TB
MDR-TBMDR-TB
MDR-TB
 
Mdr tuberculosis
Mdr tuberculosisMdr tuberculosis
Mdr tuberculosis
 
Mdr tb & xdr tb ppt.
Mdr tb & xdr tb ppt. Mdr tb & xdr tb ppt.
Mdr tb & xdr tb ppt.
 
Principle of mdr tb management
Principle of mdr tb managementPrinciple of mdr tb management
Principle of mdr tb management
 
New agents for the treatment of drug resistant Mycobacterium Tuberculosis
New agents for the treatment of drug resistant Mycobacterium TuberculosisNew agents for the treatment of drug resistant Mycobacterium Tuberculosis
New agents for the treatment of drug resistant Mycobacterium Tuberculosis
 
Mdr xdr TB
Mdr xdr TBMdr xdr TB
Mdr xdr TB
 
XDR TB
XDR TBXDR TB
XDR TB
 
Recent Advances in Multidrug-Resistant TB of HIV/TB coinfection.2013
Recent Advances in Multidrug-Resistant TB of HIV/TB coinfection.2013Recent Advances in Multidrug-Resistant TB of HIV/TB coinfection.2013
Recent Advances in Multidrug-Resistant TB of HIV/TB coinfection.2013
 
MDR TB
MDR TB MDR TB
MDR TB
 

Similar to Drugresistanttuberculosis 100227020029 Phpapp01

IN VITRO STUDY OF A MULTI DRUG RESISTANT MYCOBACTERIA AND EFFECT OF HERBAL DR...
IN VITRO STUDY OF A MULTI DRUG RESISTANT MYCOBACTERIA AND EFFECT OF HERBAL DR...IN VITRO STUDY OF A MULTI DRUG RESISTANT MYCOBACTERIA AND EFFECT OF HERBAL DR...
IN VITRO STUDY OF A MULTI DRUG RESISTANT MYCOBACTERIA AND EFFECT OF HERBAL DR...
Dr Dhanji Rajani
 
Rapid diagnosis of drug resistant tuberculosis: current perspectives and chal...
Rapid diagnosis of drug resistant tuberculosis: current perspectives and chal...Rapid diagnosis of drug resistant tuberculosis: current perspectives and chal...
Rapid diagnosis of drug resistant tuberculosis: current perspectives and chal...Dr Muktikesh Dash, MD, PGDFM
 
Drug resistant tuberculosis: A diagnostic challenge
Drug resistant tuberculosis: A diagnostic challengeDrug resistant tuberculosis: A diagnostic challenge
Drug resistant tuberculosis: A diagnostic challengeDr Muktikesh Dash, MD, PGDFM
 
TB
TBTB
MOLECULAR BASIS & MECHANISMS OF DRUG RESISTANCE IN MYCOBACTERIUM TUBERCULOSIS
MOLECULAR BASIS & MECHANISMS OF DRUG RESISTANCE IN MYCOBACTERIUM TUBERCULOSISMOLECULAR BASIS & MECHANISMS OF DRUG RESISTANCE IN MYCOBACTERIUM TUBERCULOSIS
MOLECULAR BASIS & MECHANISMS OF DRUG RESISTANCE IN MYCOBACTERIUM TUBERCULOSIS
Kalai Arasan
 
An Overview of Chemotherapy of Tuberculosis: A Review
An Overview of Chemotherapy of Tuberculosis: A ReviewAn Overview of Chemotherapy of Tuberculosis: A Review
An Overview of Chemotherapy of Tuberculosis: A Review
Jing Zang
 
Tuberculosis treatment
Tuberculosis treatmentTuberculosis treatment
Tuberculosis treatment
Daniel David
 
Tb seminar by rs
Tb seminar by rsTb seminar by rs
Tb seminar by rs
Rafi Bhat
 
Pulmonary Tuberculosis Presentation
Pulmonary Tuberculosis PresentationPulmonary Tuberculosis Presentation
Pulmonary Tuberculosis Presentation
Jack Frost
 
Multiple drug resistance
Multiple drug resistanceMultiple drug resistance
Multiple drug resistance
Abdullah Memon
 
MDR/XDR by Dr Tasleem Arif
MDR/XDR by Dr Tasleem ArifMDR/XDR by Dr Tasleem Arif
MDR/XDR by Dr Tasleem Arif
TASLEEM ARIF
 
Mdr, xdr by dr tasleem arif
Mdr, xdr by dr tasleem arifMdr, xdr by dr tasleem arif
Mdr, xdr by dr tasleem arif
TASLEEM ARIF
 
High prevalence of DR-TB (drug-resistant tuberculosis): An Indicator of publi...
High prevalence of DR-TB (drug-resistant tuberculosis): An Indicator of publi...High prevalence of DR-TB (drug-resistant tuberculosis): An Indicator of publi...
High prevalence of DR-TB (drug-resistant tuberculosis): An Indicator of publi...
Madiha Mushtaque
 
MDR-TB
MDR-TBMDR-TB
MDR-TB
9925752690
 
Recent Advances in Multidrug-Resistant TB of HIV/TB coinfection.2013
Recent Advances in Multidrug-Resistant TB of HIV/TB coinfection.2013Recent Advances in Multidrug-Resistant TB of HIV/TB coinfection.2013
Recent Advances in Multidrug-Resistant TB of HIV/TB coinfection.2013
hivlifeinfo
 
MDR , XDR
MDR , XDRMDR , XDR
MDR , XDR
vanitha gopal
 
article 2.pdf
article 2.pdfarticle 2.pdf
article 2.pdf
mumann
 
Multi Drug Resistance Assay: A new Dimension for Host Directed therapy
Multi Drug Resistance Assay: A new Dimension for Host Directed therapyMulti Drug Resistance Assay: A new Dimension for Host Directed therapy
Multi Drug Resistance Assay: A new Dimension for Host Directed therapy
Cyril Jose
 
Tuberculosis Noon Conference 2007
Tuberculosis Noon Conference 2007Tuberculosis Noon Conference 2007
Tuberculosis Noon Conference 2007
migmad
 

Similar to Drugresistanttuberculosis 100227020029 Phpapp01 (20)

IN VITRO STUDY OF A MULTI DRUG RESISTANT MYCOBACTERIA AND EFFECT OF HERBAL DR...
IN VITRO STUDY OF A MULTI DRUG RESISTANT MYCOBACTERIA AND EFFECT OF HERBAL DR...IN VITRO STUDY OF A MULTI DRUG RESISTANT MYCOBACTERIA AND EFFECT OF HERBAL DR...
IN VITRO STUDY OF A MULTI DRUG RESISTANT MYCOBACTERIA AND EFFECT OF HERBAL DR...
 
Rapid diagnosis of drug resistant tuberculosis: current perspectives and chal...
Rapid diagnosis of drug resistant tuberculosis: current perspectives and chal...Rapid diagnosis of drug resistant tuberculosis: current perspectives and chal...
Rapid diagnosis of drug resistant tuberculosis: current perspectives and chal...
 
Sdrajani
SdrajaniSdrajani
Sdrajani
 
Drug resistant tuberculosis: A diagnostic challenge
Drug resistant tuberculosis: A diagnostic challengeDrug resistant tuberculosis: A diagnostic challenge
Drug resistant tuberculosis: A diagnostic challenge
 
TB
TBTB
TB
 
MOLECULAR BASIS & MECHANISMS OF DRUG RESISTANCE IN MYCOBACTERIUM TUBERCULOSIS
MOLECULAR BASIS & MECHANISMS OF DRUG RESISTANCE IN MYCOBACTERIUM TUBERCULOSISMOLECULAR BASIS & MECHANISMS OF DRUG RESISTANCE IN MYCOBACTERIUM TUBERCULOSIS
MOLECULAR BASIS & MECHANISMS OF DRUG RESISTANCE IN MYCOBACTERIUM TUBERCULOSIS
 
An Overview of Chemotherapy of Tuberculosis: A Review
An Overview of Chemotherapy of Tuberculosis: A ReviewAn Overview of Chemotherapy of Tuberculosis: A Review
An Overview of Chemotherapy of Tuberculosis: A Review
 
Tuberculosis treatment
Tuberculosis treatmentTuberculosis treatment
Tuberculosis treatment
 
Tb seminar by rs
Tb seminar by rsTb seminar by rs
Tb seminar by rs
 
Pulmonary Tuberculosis Presentation
Pulmonary Tuberculosis PresentationPulmonary Tuberculosis Presentation
Pulmonary Tuberculosis Presentation
 
Multiple drug resistance
Multiple drug resistanceMultiple drug resistance
Multiple drug resistance
 
MDR/XDR by Dr Tasleem Arif
MDR/XDR by Dr Tasleem ArifMDR/XDR by Dr Tasleem Arif
MDR/XDR by Dr Tasleem Arif
 
Mdr, xdr by dr tasleem arif
Mdr, xdr by dr tasleem arifMdr, xdr by dr tasleem arif
Mdr, xdr by dr tasleem arif
 
High prevalence of DR-TB (drug-resistant tuberculosis): An Indicator of publi...
High prevalence of DR-TB (drug-resistant tuberculosis): An Indicator of publi...High prevalence of DR-TB (drug-resistant tuberculosis): An Indicator of publi...
High prevalence of DR-TB (drug-resistant tuberculosis): An Indicator of publi...
 
MDR-TB
MDR-TBMDR-TB
MDR-TB
 
Recent Advances in Multidrug-Resistant TB of HIV/TB coinfection.2013
Recent Advances in Multidrug-Resistant TB of HIV/TB coinfection.2013Recent Advances in Multidrug-Resistant TB of HIV/TB coinfection.2013
Recent Advances in Multidrug-Resistant TB of HIV/TB coinfection.2013
 
MDR , XDR
MDR , XDRMDR , XDR
MDR , XDR
 
article 2.pdf
article 2.pdfarticle 2.pdf
article 2.pdf
 
Multi Drug Resistance Assay: A new Dimension for Host Directed therapy
Multi Drug Resistance Assay: A new Dimension for Host Directed therapyMulti Drug Resistance Assay: A new Dimension for Host Directed therapy
Multi Drug Resistance Assay: A new Dimension for Host Directed therapy
 
Tuberculosis Noon Conference 2007
Tuberculosis Noon Conference 2007Tuberculosis Noon Conference 2007
Tuberculosis Noon Conference 2007
 

Recently uploaded

Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
bkling
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
touseefaziz1
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
Anujkumaranit
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
Jim Jacob Roy
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
MedicoseAcademics
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Dr KHALID B.M
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
Rohit chaurpagar
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
Catherine Liao
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 
Surgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptxSurgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptx
jval Landero
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
Swetaba Besh
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Oleg Kshivets
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
DrSathishMS1
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
Shweta
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
KafrELShiekh University
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Dr Jeenal Mistry
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
greendigital
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 

Recently uploaded (20)

Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 
Surgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptxSurgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptx
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
 

Drugresistanttuberculosis 100227020029 Phpapp01

  • 1. Drug Resistant Tuberculosis A Great Human Concern Dr.T.V.Rao MD
  • 2. MDR TB –Great Human Concern
  • 3.
  • 4. A Tribute to Robert Koch Discoverer of Mycobacterium Tuberculosis
  • 5.
  • 6.
  • 7. Nobody is absolutely Immune to Tuberculosis
  • 8.
  • 9. Selman Abraham Waksman Nobel Prize for his discovery in 1952 .   
  • 10.
  • 11.
  • 12.
  • 13. Multi Drug Resistant Tuberculosis MDR-TB
  • 14.
  • 15. MDR-TB & XDR-TB THE 2008 REPORT % of MDR-TB among new TB cases 1994-2007
  • 16.
  • 18.
  • 19.
  • 20.
  • 21.
  • 22.
  • 23. Global Estimates 16,000 27,000 XDR TB 1,16,000, 4,24,000 MDR TB 1.6 million 8.8 million All forms TB Estimated Number of Deaths Estimated Number of Cases Classification
  • 24.
  • 25. Global incidence of tuberculosis Still rising as a result of the growing epidemic in Africa 0 100 200 300 400 500 600 1990 1995 2000 2005 2010 2015 Incidence per 100,000 per year World Cent. Euro, East. Europe Est Market East. Medit. Lat. America West. Pacific Sth East Asia AFR high HIV AFR low HIV
  • 26. Are we Returning to a Pre-antibiotic Era Drug susceptible TB*§ MDR-TB 1990§ XDR-TB 2006§ Total DR ? Resistance to H&R – Treatable with 2 nd line drugs Resistance to 2 nd line drugs – Treatment options seriously restricted Resistance to all available drugs – No treatment options *or limited resistance manageable with 4 drug regimen - DOTS
  • 27. WHO Surveillance and Incidence of MDR TB Dye et al. Global Burden of Multidrug-Resistant TB. JID 185(8), 2002 5.3 Ivory Cost 6.6 Dominican 5.8 Iran 3.4 India 6.0 Russia 2.8 China (DOTS) 7.7 China (non-DOTS) 9.0 Latvia 14.1 Estonia % MDR TB of all new cases Country
  • 28.
  • 29. Strains with genetic drug resistance Wild M. TB strain Acquired drug resistance Primary drug resistance Spontaneous mutation Selection: inadequate treatment Transmission Development of anti-tuberculosis drug resistance Pablos-Mendez et al. WHO, 1997
  • 30.
  • 31.
  • 32.
  • 33.
  • 35.
  • 36.
  • 37.
  • 38.
  • 39.
  • 40.
  • 41.
  • 42.
  • 43. MODS M icroscopic O bservation of D rug Susceptibility T esting
  • 44.
  • 45.
  • 46.
  • 47.
  • 48.
  • 49.
  • 50.
  • 51.
  • 52.
  • 53.
  • 54. Sample layout on MODS plate (2 samples per plate) No plate contained 2 samples from the same patient
  • 55.
  • 56.
  • 57. In MODS growth is identified by cording on Microscopy
  • 58.
  • 59.
  • 60.
  • 61.
  • 62.
  • 63. PCR: Molecular susceptibility testing RMP resistance INH resistance Hain Genotype MTBDR Hain Genotype MTBDR INNO-LiPA Rif.TB assay
  • 64.
  • 65.
  • 66.
  • 67.
  • 68. Lower Grade Biosafety is adequate
  • 69. N 95 mask protects from Biohazard
  • 70.
  • 71. Computer pattern recognition of Mycobacterium tuberculosis in MODS culture
  • 73. M . tuberculosis in MODS x10 objective (sputum sample inoculation ) Day 6 Day 16 Day 17 Day 7 Day 8 Day 9 Day 10 Day 11 Day 12 Day 13 Day 14 Day 15
  • 74. MODS can be used in Extra pulmonary Tuberculosis
  • 75.
  • 76.
  • 77.
  • 78.
  • 79.
  • 80.
  • 81.
  • 82. Microscopy and Culturing still a top priority
  • 83.
  • 84. No testing method replaces clinical assessment
  • 85.
  • 86.
  • 87. Czech Republic The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.  WHO 2005. All rights reserved Ecuador Georgia Argentina Bangladesh Germany Republic of Korea Armenia Russian Federation South Africa Portugal Latvia Mexico Peru USA Brazil UK Sweden Thailand Chile Based on information provided to WHO Stop TB Department 13 September 2007 Spain Islamic Republic of Iran China, Hong Kong SAR France Japan Norway Canada Italy Netherlands Estonia Lithuania Ireland Romania Israel Azerbaijan Poland Slovenia India Australia Mozambique Vietnam Countries with confirmed XDR-TB cases as of September 2007
  • 88.
  • 89.
  • 90.
  • 91. Are there any solutions for effective Diagnosis in TB ?
  • 92. Many more powerful hands needed to Control Tuberculosis
  • 93. Contribute your Knowledge, Wisdom, to prevent spread and control of Tuberculosis
  • 94. Created by Dr.T.V.Rao MD for ‘e’ learning Programme Email [email_address]